Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Issue: Health products
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 106 - 120 of 133 items.
Health Canada advises Canadians to exercise caution when taking gabapentin or pregabalin with opioids
AlertInformation update | 2019-09-17
Needle-free dermal filler devices used for cosmetic skin treatments are not authorized in Canada and may pose health risks
AlertInformation update | 2019-09-13
Health Canada clarifies position on Platelet Rich Plasma treatments
AlertInformation update | 2019-07-26
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
AlertHealth professional risk communication | 2019-07-22
Substance use during summer events and festivals
AlertInformation update | 2019-06-20
ALERTEC (modafinil) and the Risk of Congenital Anomalies
AlertHealth professional risk communication | 2019-06-20
Important Safety Information on Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion
AlertHealth professional risk communication | 2019-05-30
Health Canada suspends Allergan's licences for its Biocell breast implants after safety review concludes an increased risk of cancer
AlertInformation update | 2019-05-28
Health Canada is advising Canadians about the potential health risks associated with unauthorized cell therapy treatments such as stem cell therapy
AlertInformation update | 2019-05-15
Intragastric Balloons and Potential Risk of Gastric and Esophageal Perforation, Pancreatitis, and Overinflation
AlertHealth professional risk communication | 2019-04-17
PrBENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury
AlertHealth professional risk communication | 2019-04-04
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
AlertHealth professional risk communication | 2019-03-25
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
AlertHealth professional risk communication | 2019-03-13
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
AlertHealth professional risk communication | 2019-01-30
XARELTO (rivaroxaban) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement
AlertHealth professional risk communication | 2018-12-20